Stem Cell Transplant

Bone Marrow Engraftment Patent Issued Using Human Mesenchymal Stem Cells

Published in Cancer Weekly, May 4th, 1998

Osiris Therapeutics, Inc., Baltimore, Maryland, announced that the U.S. Patent & Trademark Office has issued a patent containing broad claims directed to methods for enhancing the regeneration of a patient's bone marrow using human mesenchymal stem cells (MSCs) following damage by chemotherapy or radiation treatment.

The patent, based on discoveries from Case Western Reserve University and assigned to Osiris, covers the use of MSCs in bone marrow and hematopoietic stem cell transplants to reconstitute bone marrow stroma, the connective tissue in bone marrow upon which blood cell formation occurs.

Osiris has been engaged in the research and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-05-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry